Hyman Charles D Vertex Pharmaceuticals Inc Call Options Transaction History
Hyman Charles D
- $1.79 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRTX
# of Institutions
1,724Shares Held
222MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.4 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.7 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.84 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.46 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.16 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $119B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...